Table 2.
Clinical and laboratory characteristics, and follow-up outcome of the study participants on Pre-ART follow up, JUSH, 2013, N = 588
| Variables | Category | Pre-ART | Total | |
|---|---|---|---|---|
| IPT group No (%) | Non-IPT group No (%) | |||
| Past opportunistic infection(n = 587) | Yes | 145 (49.49%) | 126 (42.86%) | 271 (46.17%) |
| No | 148 (50.51%) | 168 (57.14%) | 316 (53.83%) | |
| WHO clinical stage | Stage I/ II | 256 (87.07%) | 227 (77.21%) | 483 (82.14%) |
| Stage III/ IV | 38 (12.93%) | 67 (22.79%) | 105 (17.86%) | |
| Functional status | Working1 | 270 (91.84%) | 250 (85.03%) | 520 (88.44%) |
| Ambulatory2 | 22 (7.48%) | 43 (14.63%) | 65 (11.05%) | |
| Bedridden3 | 2 (0.68%) | 1 (0.34%) | 3 (0.51%) | |
| OI treatment other than INH (n = 584) | Given4 | 143 (49.14%) | 124 (42.32%) | 267 (45.72%) |
| Not given | 148 (50.86%) | 169 (57.68%) | 317 (54.28%) | |
| Hemoglobin level (n = 532) | <=10 mg/dl | 16 (5.90%) | 19 (7.28%) | 35 (6.58%) |
| >10 mg/dl | 255 (94.10%) | 242 (92.72%) | 497 (93.42%) | |
| CD 4 cells count (cells/μl) (n = 585) | <350 | 84 (28.77%) | 69 (23.55%) | 153 (26.15%) |
| 350 – 499 | 121 (41.44%) | 116 (39.59%) | 237 (40.51%) | |
| > = 500 | 87 (29.79%) | 108 (36.86%) | 195 (33.33%) | |
| Weight (kg) | <40 | 3 (1.02%) | 13 (4.42%) | 16 (2.72%) |
| 40-49 | 81 (27.55%) | 87 (29.59%) | 168 (28.57%) | |
| 50-60 | 117 (39.63%) | 129 (43.88%) | 246 (41.84%) | |
| >60 | 93 (31.63%) | 65 (22.11%) | 158 (26.87%) | |
| Follow-up outcome | Alive | 181 (61.56%) | 105 (35.71%) | 286 (48.64%) |
| Lost to follow up | 66 (22.45%) | 109 (37.07%) | 175 (29.76%) | |
| Entry to ART | 20 (6.8%) | 19 (6.46%) | 39 (6.63%) | |
| TB | 13 (4.42%) | 36 (12.24%) | 49 (8.83%) | |
| Other5 | 14 (4.76%) | 25 (8.50%) | 39 (6.63%) | |
| Median CD 4 cells count (cells/μl) | 415 (IQR 328–786) | 444 (IQR 357–613) | 422 (IQR 344–589) | |
1Working: able to perform usual work in and out of the house.
2Ambulatory: able to perform activities for daily living.
3Bedridden: unable to perform activities for daily living.
4Cotrimoxazole, Fluconazole.
5Transferred out and dead.